Answers are grounded in this paper and cite their sources.
Analysis reveals KRAS regulates EV charge and secretion in pancreatic cancer, suggesting new liquid biopsy potential.
Extracellular vesicles (EVs) have the potential to be used as a liquid biopsy for cancer detection and treatment response assessment. Although the potential of EVs as disease-specific biomarkers has been promising, the rapid and specific enrichment of EVs from body fluids in the clinical setting remains challenging. To address this limitation, we developed a Microfluidic Electrophoresis (MEP) device, that allows label-free enrichment of EVs based on charge from the serum of patients with pancreatic cancer (PaCa). The ability of MEP to enrich anionic EVs was validated using cell line-derived EVs and PaCa serum-derived EVs. We observed a positive correlation between the KRAS status, secretion of EVs, and net negative zeta potential ζ of EVs. Further analyses identified phosphatidylserine (PS) and extraluminal DNA as molecular determinants of the enhanced anionic nature of PaCa-derived EVs. Overall, this work introduces a new microfluidic device to enrich cancer EVs in circulation with potential for further rapid detection of PaCa.
No takes yet. Share an insight, caveat, or question.
Kapoor et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: